Centaurus

Centaurus Biopharma is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of novel small molecule drugs. The company focuses on high-impact therapeutic areas, particularly oncology and metabolic disorders, utilizing a robust internal research and development engine. Its pipeline features a variety of targeted therapies, including inhibitors of FGFR and IDH1/2, which are currently undergoing clinical evaluation. Centaurus has a proven track record of innovation, evidenced by its strategic partnerships and licensing agreements with major pharmaceutical companies like Bayer. By combining deep expertise in medicinal chemistry with structural biology, the company aims to deliver effective treatments for patients with significant unmet medical needs.